Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.
Peptide A
Healing & Recovery
Human antimicrobial peptide with broad-spectrum pathogen defense and wound-healing activity.
Peptide B
Healing & Recovery
The 7-amino-acid active fragment of TB-500, isolated for cell-migration effects.
Typical vial
5 mg
Typical dose
50-100 mcg
Half-life
~15-30 minutes (rapidly degraded by proteases)
FDA status
Not FDA approved for human use.
Typical vial
10 mg
Typical dose
2000-5000 mcg
Half-life
Estimated minutes to a few hours (much shorter than full TB-500 due to lack of N/C-terminal protection)
FDA status
Not FDA approved for any human or veterinary use. No clinica…
LL-37 effects
TB-500 Fragment 17-23 effects
LL-37 side effects
TB-500 Fragment 17-23 side effects
LL-37 dosing ranges
Antimicrobial support
50-100 mcg · Once daily (SubQ) · 2-4 weeks
Wound healing support
50-100 mcg · Once daily near affected area · 2-4 weeks
TB-500 Fragment 17-23 dosing ranges
Injury recovery (extrapolated)
2-5 mg · Twice weekly SubQ · 4-6 weeks
Tendon/ligament support (extrapolated)
2-5 mg · Twice weekly SubQ · 4-8 weeks
Loading phase (anecdotal)
5 mg · Twice weekly for 2-3 weeks · Then maintenance
LL-37: Human antimicrobial peptide with broad-spectrum pathogen defense and wound-healing activity. Typical dose 50-100 mcg. TB-500 Fragment 17-23: The 7-amino-acid active fragment of TB-500, isolated for cell-migration effects. Typical dose 2000-5000 mcg. Both fall under the Healing & Recovery category.
Stacking LL-37 with TB-500 Fragment 17-23 is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.
LL-37 is typically dosed: Once daily (SubQ) for Antimicrobial support; Once daily near affected area for Wound healing support. TB-500 Fragment 17-23 is typically dosed: Twice weekly SubQ for Injury recovery (extrapolated); Twice weekly SubQ for Tendon/ligament support (extrapolated); Twice weekly for 2-3 weeks for Loading phase (anecdotal).
LL-37: Not FDA approved for human use. TB-500 Fragment 17-23: Not FDA approved for any human or veterinary use. No clinical trials have been conducted on this specific fragment.
Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.
Get Started Free